Back to Journals » Cancer Management and Research » Volume 4
New drugs and combinations for the treatment of soft-tissue sarcoma: a review
Authors Somaiah , von Mehren M
Received 12 July 2012
Accepted for publication 27 September 2012
Published 23 November 2012 Volume 2012:4 Pages 397—411
DOI https://doi.org/10.2147/CMAR.S23257
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Neeta Somaiah,1 Margaret von Mehren2
1Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Abstract: Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors.
Keywords: soft tissue sarcoma, clinical trials, trabectedin, palifosfamide, pazopanib
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.